

On January 26, 2017, Dr. Arie Belldegrun resigned as a member of the Board of Directors of Teva Pharmaceutical Industries Ltd. (the "Company"). In his resignation, Dr. Belldegrun stated his need to focus on his responsibilities as Chairman, President, CEO and Founder of Kite Pharma, Inc. as the company enters a critical juncture in its growth with important milestones anticipated in 2017. Dr. Belldegrun joined Teva's Board of Directors in 2013 and would have stood for election at the 2019 annual meeting. The Company thanks Dr. Belldegrun for his years of dedicated service and wishes him well in his other endeavors.

ד"ר אריה בלדגרין התפטר מחברותו בדירקטוריון טבע. ד"ר בלדגרין ציין כי הוא מתפטר מהדירקטוריון בכדי שהוא יוכל להתמקד באופן מלא באחריותו כיו"ר, נשיא, מנכ"ל ומייסד של קייט פארמה [וכי החלטתו להתפטר לא באה כתוצאה מחילוקי דעות עם החברה, פעילותה, מדיניותה או התנהלותה]. ד"ר בלדגרין הצטרף לדירקטוריון טבע ב- 2013 ועמד בפני בחירה מחודשת באסיפה השנתית של 2019. החברה מודה לד"ר בלדגרין על שנות שירותו המסור ומאחלת לו כל טוב בכל פועלו.

העתק ממכתב התפטרותו של ד"ר בלדגרין מובא להלן:

A copy of Dr. Belldegrun's resignation letter is below:

Yitzhak Peterburg, M.D.
Chairman of the Board
Teva Pharmaceuticals

Dear Dr. Peterburg:

I have had the privilege to serve as a Director of Teva Pharma since 2013. During the same time, I have gradually expanded my executive responsibilities as Chairman, President and Chief Executive Officer of Kite Pharma. Given my confidence in the future of Teva, and my commitment to Kite, I have reached the difficult conclusion that I must relinquish my role as a director for Teva in order to serve Kite's shareholders and employees at this critical juncture in Kite's growth. With several critical milestones on the horizon for Kite and the responsibilities these developments will entail, I am compelled to step down from my role on the Board of Teva and hereby request my resignation, effective January 26, 2017.

Kite has grown in the past three years from eight employees to over 420 employees, and we are leading a revolution in cancer therapy with our lead product candidate, KTE-C19, an engineered T cell immunotherapy with the potential to transform the treatment of hematological cancers. Last week, we announced that we met with the FDA for a pre-BLA meeting and as a result, we will be initiating a rolling submission for the first ever CAR-T therapy in December 2016. We also remain on track for commercial launch in 2017. I do not take the responsibility of advancing a potentially life saving therapy for cancer patients lightly. The same holds true as I think of the needs of Teva Pharmaceuticals and its ability to reach millions of patients with its life-saving products.

The improvement of patient health and wellbeing has been my life's work. From my early days at the National Cancer Institute, to my time as a UCLA Professor and surgeon, to the good fortune I have today as I work with leaders in the healthcare industry, I have embraced the never-ending challenge to make a difference for patients around the world.

It has been a personal honor to serve on Teva's Board of Directors for the last three years. My enthusiasm for Teva has only grown during my tenure as the Chair of the Science and Technology committee. In my view, no other global life science company has the same breadth of opportunity to protect the health of people around the world. Teva is prepared for a bright and dynamic future, and I hope I assisted to further your efforts in my roles. When I look around the table during our regular Board meetings, I am impressed by the hard work and dedication of the members of the Board and their commitment to the company and its highly talented management. Unfortunately, at the present time, I cannot devote the time Teva needs and deserves.

While I regret the need for my departure from Teva's Board at this time, I remain firmly committed to the company's success. I encourage the Board to remain innovative and courageous in this ever-changing environment, as you look to do what is best for shareholders and patients alike. I promise to continue to support Teva in any way possible and thank you for the opportunity to serve the world's greatest generic company and jewel of Israel's industry.

With best personal regards,

/s/ Arie Beldegrun, M.D., FACS